Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 6/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882800 | 0.88 | F2R (0.67) | F2RKCNK3TP53SMN1; SMN2HTT | |
| SCHEMBL8278749 | 0.87 | F2R (0.65) | F2RMAPTSMN1; SMN2HTTMEN1 | |
| SCHEMBL10069466 | 0.86 | F2R (0.82) | F2RKCNK3KCNK9TP53SMN1; SMN2 | |
| SCHEMBL882782 | 0.84 | F2R (0.70) | F2RTP53SMN1; SMN2HTTMEN1 | |
| SCHEMBL882778 | 0.83 | F2R (1.00) | F2RKCNK3KCNK9TP53SMN1; SMN2 | |
| SCHEMBL3675463 | 0.82 | KCNK3 (0.84) | KCNK3KCNK9MAPTSMN1; SMN2HTT | |
| SCHEMBL10975643 | 0.82 | F2R (0.73) | F2RTP53MAPTRAB9A | |
| SCHEMBL10788653 | 0.81 | ALDH1A1 (0.64) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL882798 | 0.81 | F2R (0.68) | F2RTP53SMN1; SMN2HTTNPC1 | |
| SCHEMBL882793 | 0.81 | F2R (0.66) | F2RTP53SMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | F2R 1/4885KCNK3 4408/4885KCNK9 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.